CLINICAL_TRIALS
trial_result
· 2022-05-26
Clinical Trial Update: A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children [Phase 3]
Summary
Phase 3 clinical trial evaluating lanadelumab for preventing hereditary angioedema attacks in children has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Shire | Conditions: Hereditary Angioedema | Phase 3 | Status: COMPLETED | Results posted: 2022-05-26